leadf
logo-loader
viewQ BioMed Inc.

Q BioMed CEO says Strontium89 has received a warm response and enthusiasm from physicians

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the biotech has seen commercial uptake of Strontium89, its FDA-approved drug for the non-opioid treatment of metastatic cancer in the bone. Corin says while the coronavirus pandemic slowed the diagnosis and treatment of cancer in many patients throughout spring and into summer, limited the industry's access to physicians, the reintroduction of Strontium89 has received a warm response and enthusiasm from physicians, who are pleased that it is once again available for the benefit of their patients.

Quick facts: Q BioMed Inc.

Price: 1.08 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $25.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Q BioMed gets US patent for its Uttrocide-B molecule as a potential liver...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has received a US patent for its Uttrocide-B molecule as a potential liver cancer treatment. Corin says the company now has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology,...

1 week, 6 days ago

2 min read